HPV-associated penile cancer: Impact of copy number alterations in miRNA/mRNA interactions and potential druggable targets

Cancer Biomark. 2021;32(2):147-160. doi: 10.3233/CBM-210035.

Abstract

Background: Penile cancer (PeCa) is a rare disease, but its incidence has increased worldwide, mostly in HPV+ patients. Nevertheless, there is still no targeted treatment for this carcinoma.

Objective: To predict the main signaling pathways involved in penile tumorigenesis and its potential drug targets.

Methods: Genome-wide copy number profiling was performed in 28 PeCa. Integration analysis of CNAs and miRNAs and mRNA targets was performed by DIANA-TarBase v.8. The potential impact of the miRNAs/target genes on biological pathways was assessed by DIANA-miRPath v.3.0. For each miRNA, KEGG pathways were generated based on the tarbase and microT-CDS algorithms. Pharmaco-miR was used to identify associations between miRNAs and their target genes to predict druggable targets.

Results: 269 miRNAs and 2,395 genes were mapped in cytobands with CNAs. The comparison of the miRNAs mapped at these cytobands and the miRNAs that were predicted to regulate the genes also mapped in these regions, resulted in a set of common 35 miRNAs and 292 genes. Enrichment pathway revealed their involvement in five top signaling pathways. EGFR and COX2 were identified as potential druggable targets.

Conclusion: Our data indicate the potential use of EGFR and COX2 inhibitors as a target treatment for PeCa patients.

Keywords: Genomic profiling; biomarkers; human papillomavirus; molecular target; penile tumor.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Biomarkers, Tumor / antagonists & inhibitors
  • Biomarkers, Tumor / genetics*
  • Biomarkers, Tumor / metabolism
  • Carcinogenesis / genetics
  • Carcinoma / drug therapy
  • Carcinoma / genetics*
  • Carcinoma / pathology
  • Carcinoma / virology
  • Cyclooxygenase 2 / genetics
  • Cyclooxygenase 2 Inhibitors / pharmacology
  • Cyclooxygenase 2 Inhibitors / therapeutic use
  • DNA Copy Number Variations
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / genetics
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Male
  • MicroRNAs / metabolism
  • Middle Aged
  • Molecular Targeted Therapy / methods
  • Papillomavirus Infections / drug therapy
  • Papillomavirus Infections / genetics*
  • Papillomavirus Infections / pathology
  • Papillomavirus Infections / virology
  • Penile Neoplasms / drug therapy
  • Penile Neoplasms / genetics*
  • Penile Neoplasms / pathology
  • Penile Neoplasms / virology
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • RNA, Messenger / metabolism
  • Signal Transduction / genetics

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Cyclooxygenase 2 Inhibitors
  • MicroRNAs
  • Protein Kinase Inhibitors
  • RNA, Messenger
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • EGFR protein, human
  • ErbB Receptors